Skip to main content
Clinical Trials/NCT03854188
NCT03854188
Withdrawn
Not Applicable

Acupuncture for Relieving Chronic Pelvic Pain

William Xu, MD0 sitesJanuary 1, 2021
ConditionsPelvic Pain

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pelvic Pain
Sponsor
William Xu, MD
Primary Endpoint
Measure pelvic specific pain
Status
Withdrawn
Last Updated
5 years ago

Overview

Brief Summary

Individuals with chronic pelvic pain will be identified, consented and enrolled in this study in which acupuncture will be offered in addition to current standards of care. The primary outcome will assess if there is a reduction of pain intensity from the baseline to 6 months as a result of treatment.

Detailed Description

Chronic pelvic pain as defined by the American College of Obstetricians and Gynecologists is "noncyclic pain of 6 or more months duration that localizes to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back or the buttocks and is of sufficient severity to cause functional disability or lead to medical care". This has devastating consequences both monetarily as well as emotionally and can lead to opioid addiction, depression and even suicide. Acupuncture has been used to treat pain in China for millenniums and was one of the more effective ways to treat pain before morphine was discovered. Acupuncture is feasible, economic and a safe way to treat chronic pain. Patients with chronic pelvic pain will be identified and offered participation in the study. After the consent process is completed, patients will undergo a brief physical exam to rule out acute symptoms. The patient will be asked to complete a baseline pain inventory and genitourinary pain index survey before proceeding with acupuncture treatment. Qualified patients will be requested to accept acupuncture treatments twice weekly for 12 consecutive weeks. Each week the patient will be asked to report their current medications and changes in the dosage as well as their narcotic (opioid) doses and any changes in the dosages. Patients will be followed up monthly for up to 3 months after treatment completion by phone to record their pain inventory as well as their genitourinary pain index survey.

Registry
clinicaltrials.gov
Start Date
January 1, 2021
End Date
December 31, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
William Xu, MD
Responsible Party
Sponsor Investigator
Principal Investigator

William Xu, MD

Associate Anesthesiologist

University of Iowa

Eligibility Criteria

Inclusion Criteria

  • Chronic pelvic pain persisting for at least 6 months
  • English speaking
  • Able to provide informed consent

Exclusion Criteria

  • Unable to provide informed consent
  • Prisoners
  • Morbid obesity (BMI \>40, or \> 36 associated with hypertension and diabetes)
  • Severe cardiac disease
  • Active chemotherapy or radiation therapy
  • Skin infections or lesions
  • Severe COPD
  • Neuropathy
  • Previous stroke
  • Paralysis

Outcomes

Primary Outcomes

Measure pelvic specific pain

Time Frame: Three months

Subjects will report baseline pain scores using the Genitourinary Pain Index (GUPI). The index is used to quantify the severity of pelvic pain experienced by the patient. It is a self-reporting condition specific questionnaire (gender specific) that is scored based on information provided by the patient. The scale is 0 to 5 with 0 indicating never experienced and 5 indicating being always present. The same index will be used at the end of treatment to determine the post-treatment scores and compared to baseline scores.

Measure generalized body pain

Time Frame: Three months

Subjects will report initial baseline pain scores using the Brief Pain Inventory (BPI). The BPI assesses the severity of pain experienced by the patient and calculates pain's impact on daily functioning. It is self-reported and uses a numerical scale where 0 indicates no pain and 10 indicating pain as bad as the patient can image. The patient will report again using the BPI at the end of treatment and the values obtained will be compared to the baseline scores.

Secondary Outcomes

  • Measure pain score after treatment-1 month (BPI)(One month post treatment)
  • Measure pain score after treatment-1 month (GUPI)(One month post treatment)
  • Measure pain score after treatment-3 months (GUPI)(Three months post treatment)
  • Measure pain score after treatment-2 months (GUPI)(Two months post treatment)
  • Measure pain score after treatment-2 months (BPI)(Two months post treatment)
  • Measure pain score after treatment-3 months (BPI)(Three months post treatment)

Similar Trials